Phase II AZD9291 Open Label Study in NSCLC After Previous EGFR TKI Therapy in EGFR and T790M Mutation Positive Tumours

PHASE2CompletedINTERVENTIONAL
Enrollment

210

Participants

Timeline

Start Date

May 20, 2014

Primary Completion Date

May 1, 2015

Study Completion Date

November 7, 2023

Conditions
Non Small Cell Lung Cancer
Interventions
DRUG

AZD9291

Once daily tablet 80 mg

Trial Locations (44)

112

Research Site, Taipei

10032

Research Site, New York

10408

Research Site, Goyang-si

13620

Research Site, Seongnam-si

15006

Research Site, A Coruña

20132

Research Site, Milan

20141

Research Site, Milan

27710

Research Site, Durham

28007

Research Site, Madrid

28222

Research Site, Majadahonda

29010

Research Site, Málaga

37134

Research Site, Verona

40705

Research Site, Taichung

46026

Research Site, Valencia

46202

Research Site, Indianapolis

80131

Research Site, Napoli

92093

Research Site, La Jolla

92868

Research Site, Orange

06510

Research Site, New Haven

06850

Research Site, Norwalk

02215

Research Site, Boston

03756

Research Site, Lebanon

T6G 1Z2

Research Site, Edmonton

K1H 8L6

Research Site, Ottawa

M5G 2M9

Research Site, Toronto

Unknown

Research Site, Hong Kong

00000

Research Site, Shatin

06132

Research Site, Perugia

673-8558

Research Site, Akashi-shi

104-0045

Research Site, Chūōku

362-0806

Research Site, Kitaadachi-gun

802-0077

Research Site, Kitakyushu-shi

135-8550

Research Site, Kōtoku

460-0001

Research Site, Nagoya

464-8681

Research Site, Nagoya

951-8566

Research Site, Niigata

534-0021

Research Site, Osaka

541-8567

Research Site, Osaka

591-8555

Research Site, Sakaishi

589-8511

Research Site, Sayama

641-8510

Research Site, Wakayama

236-0051

Research Site, Yokohama

06591

Research Site, Seoul

08025

Research Site, Barcelona

Sponsors

Lead Sponsor

All Listed Sponsors
lead

AstraZeneca

INDUSTRY